Theratechnologies (NASDAQ:THTX - Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.08), Zacks reports. The business had revenue of $17,729 billion during the quarter, compared to analysts' expectations of $24.30 million.
Theratechnologies Stock Performance
NASDAQ:THTX traded up $0.02 during trading hours on Thursday, reaching $3.16. The stock had a trading volume of 239,711 shares, compared to its average volume of 1,671,150. Theratechnologies has a 52 week low of $1.12 and a 52 week high of $3.20. The company has a 50 day moving average price of $2.63 and a two-hundred day moving average price of $2.09. The stock has a market capitalization of $145.07 million, a PE ratio of -39.44 and a beta of 0.55.
Institutional Investors Weigh In On Theratechnologies
A hedge fund recently bought a new stake in Theratechnologies stock. Acadian Asset Management LLC purchased a new stake in Theratechnologies Inc. (NASDAQ:THTX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 28,400 shares of the company's stock, valued at approximately $39,000. Acadian Asset Management LLC owned approximately 0.06% of Theratechnologies as of its most recent SEC filing.
Analyst Ratings Changes
Separately, Jones Trading cut Theratechnologies from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 3rd.
Check Out Our Latest Stock Analysis on THTX
About Theratechnologies
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Further Reading
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
